We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+2.06%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$342M
AUM Growth
+$4.53M
Cap. Flow
+$2.54M
Cap. Flow %
0.74%
Top 10 Hldgs %
27.24%
Holding
105
New
9
Increased
44
Reduced
37
Closed
6

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$8.51M
2
UHS icon
Universal Health Services
UHS
+$7.3M
3
ABBV icon
AbbVie
ABBV
+$6.16M
4
RAD
Rite Aid Corporation
RAD
+$5.54M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$4.74M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$10.6M
2
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$8.41M
3
CELG
Celgene Corp
CELG
+$6.93M
4
BIIB icon
Biogen
BIIB
+$6.92M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$5.75M

Sector Composition

Rank Sector Weight
1 Healthcare 78.72%
2 Financials 1.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
26
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$4.4M 1.29%
+18,600
New +$4.74M
CYH icon
27
Community Health Systems
CYH
$423M
$4.33M 1.27%
95,590
-27,830
-23% -$1.16M
MCK icon
28
McKesson
MCK
$101B
$4.28M 1.25%
22,000
+500
+2% +$96.2K
DXCM icon
29
DexCom
DXCM
$32B
$4.24M 1.24%
424,000
+24,000
+6% +$245K
ELV icon
30
Elevance Health
ELV
$85.5B
$4.19M 1.23%
35,000
+7,000
+25% +$803K
HCA icon
31
HCA Healthcare
HCA
$89.5B
$4.09M 1.2%
58,000
-2,000
-3% -$132K
CTRX
32
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$3.92M 1.15%
93,000
+23,000
+33% +$1.05M
COR icon
33
Cencora
COR
$61.2B
$3.87M 1.13%
50,000
+21,500
+75% +$1.63M
MRK icon
34
Merck
MRK
$318B
$3.85M 1.13%
68,120
-13,624
-17% -$765K
MDVN
35
DELISTED
MEDIVATION, INC.
MDVN
$3.76M 1.1%
76,000
-28,000
-27% -$1.19M
THOR
36
DELISTED
THORATEC CORPORATION
THOR
$3.58M 1.05%
133,800
+66,300
+98% +$1.88M
STJ
37
DELISTED
St Jude Medical
STJ
$3.43M 1%
57,000
+17,000
+43% +$1.11M
AMGN icon
38
Amgen
AMGN
$222B
$3.23M 0.95%
23,000
+8,000
+53% +$1.04M
TEVA icon
39
Teva Pharmaceuticals
TEVA
$41.2B
$3.17M 0.93%
59,000
+34,000
+136% +$1.8M
UNH icon
40
UnitedHealth
UNH
$370B
$3.02M 0.88%
35,000
+3,000
+9% +$254K
ABMD
41
DELISTED
Abiomed Inc
ABMD
$3M 0.88%
120,736
+13,736
+13% +$348K
AGN
42
DELISTED
Allergan Inc
AGN
$2.94M 0.86%
16,500
-23,500
-59% -$3.9M
MASI
43
DELISTED
Masimo
MASI
$2.87M 0.84%
135,000
+48,000
+55% +$1.1M
AET
44
DELISTED
Aetna Inc
AET
$2.83M 0.83%
35,000
+20,000
+133% +$1.63M
ESRX
45
DELISTED
Express Scripts Holding Company
ESRX
$2.75M 0.81%
39,000
+29,000
+290% +$2.07M
EIGR
46
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.68M 0.79%
570
+468
+459% +$2.47M
CLVS
47
DELISTED
Clovis Oncology, Inc.
CLVS
$2.59M 0.76%
57,000
-33,000
-37% -$1.38M
BSX icon
48
Boston Scientific
BSX
$71.5B
$2.53M 0.74%
214,000
-201,000
-48% -$2.53M
CNC icon
49
Centene
CNC
$32.5B
$2.48M 0.73%
120,000
-20,000
-14% -$386K
BCR
50
DELISTED
CR Bard Inc.
BCR
$2.43M 0.71%
17,000
+2,000
+13% +$295K
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2014 Portfolio in Review

As of Q3 2014, Rhenman & Partners Asset Management held 105 positions worth $342M, up 1.3% from $337M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management's Q3 2014 filing shows 9 new, 44 increased, 37 reduced and 6 closed positions. Its largest new stake was Medtronic: 133,800 shares worth $6.87M. The largest sale was Gilead Sciences, an estimated $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 85% a quarter earlier, followed by Financials.

  • Rhenman & Partners Asset Management's largest Q3 2014 buy was Medtronic: 133,800 shares worth $6.87M.
  • Rhenman & Partners Asset Management added most to Universal Health Services in Q3 2014, an estimated $7.3M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2014 reduction was Gilead Sciences, cutting an estimated $10.6M.
  • Rhenman & Partners Asset Management fully exited Myriad Genetics in Q3 2014, selling an estimated $3.11M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $342M portfolio in Q3 2014.
  • Rhenman & Partners Asset Management opened 9 new positions and closed 6 in Q3 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1.3% quarter-over-quarter to $342M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2014, filed 3 Nov 2014.